• Tonix Pharmaceuticals Holding Corp. published a medical research presentation outlining development of TNX-4800, investigational long-acting human monoclonal antibody designed to prevent Lyme disease by targeting Borrelia burgdorferi outer surface protein A.
• Program update highlighted Phase 1 completion with no significant clinical or laboratory safety signals, with data supporting a planned adaptive Phase 2 field study pending FDA agreement.
• Development plan calls for subcutaneous dosing in spring with a booster at 2 months, with expected protection within 2 days lasting at least 6 months.
• Milestones include Type C FDA meeting scheduled for early 3Q 2026, GMP manufacturing for human studies targeted for early 2027, with Phase 2 field study initiation planned for 1H 2027 pending FDA agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.